GPT and liver disorder: Patients with biochemical evidence of highly active CHB-related liver disease (ALT>100 U/L) had significantly higher levels of serum galectin-9 than CHB patients with ALT<50 IU/L, (p = 0.01) or healthy controls (p = 0.02).